Personalized Acromegaly Treatment System with AI, IoT, and Blockchain Integration

A novel system integrating AI-driven dosage calculation, IoT-enabled wearables, and blockchain-based patient data management to optimize treatment outcomes for acromegaly patients

The original patent relates to oral drug delivery of octreotide for treating acromegaly. However, it has limitations in terms of personalized treatment, real-time monitoring, and secure data management. The new inventive concept addresses these limitations by introducing AI, IoT, and blockchain technologies to create a more effective and efficient treatment system

The system comprises an AI-driven dosage calculator that analyzes patient data and generates personalized treatment plans. The plans are integrated with IoT-enabled wearables that monitor IGF-1 levels and clinical symptoms in real-time. The system also includes a blockchain-based patient data management platform that ensures secure and transparent data sharing. The wearable device features a nanosensor array for detecting changes in IGF-1 levels, which is connected to an AI-powered analytics platform for real-time data analysis and personalized treatment recommendations. The system also utilizes a nanomaterial-based oral dosage form for delivering octreotide with tunable release kinetics to optimize bioavailability and minimize side effects

The new claims introduce the synergistic combination of AI, IoT, blockchain, and nanomaterials to create a more powerful system for treating acromegaly. This integration of distinct technologies provides a novel and non-obvious solution that improves treatment outcomes and patient care

Alternative embodiments of the system could include the use of different AI algorithms, various IoT devices, or different blockchain platforms. The system could also be adapted for treating other diseases or conditions, such as diabetes or hypertension

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and digital health. The system could be marketed as a comprehensive solution for acromegaly treatment, with potential partnerships with pharmaceutical companies, healthcare providers, and medical device manufacturers